Navigation Links
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients

- Data Presented at AACR Annual Meeting Late-Breaking Clinical Trials

Session -

SAN FRANCISCO and SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial showed that the Company's novel androgen receptor antagonist, MDV3100, continued to reduce serum levels of prostate specific antigen (PSA), a marker of tumor growth, in the lowest expanded dose group tested after three months of treatment. Over-expression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. These observed declines were consistent with the inhibition of androgen receptor signaling. MDV3100 continued to be well-tolerated in all dose groups.

The data were presented as part of a special late-breaker clinical plenary session at the American Association for Cancer Research (AACR) Annual Meeting in San Diego. The oral presentation, entitled "Phase I-II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer," was presented by Howard Scher, M.D., chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York.

"The declines in PSA observed thus far and the general tolerability of this treatment are encouraging, and further data currently being generated will clarify its role as a potential therapy for patients with castration-resistant prostate cancer," said Dr. Scher.

"We continue to be encouraged by the results observed at this low dose of MDV3100. In addition, we are testing higher doses to assess a dose response," said David Hung, M.D., president and chief executive officer of Medivation. "The analysis of the association between PSA declines and clinical outcomes is ongoing. We look forward to providing additional results from this clinical trial at an upcoming medical conference."

The ongoing Phase 1-2 trial is an open-label U.S. study enrolling prostate cancer patients who have failed standard hormonal therapies. The study is currently planned to enroll patients in 4 dose-expansion cohorts. Of the 21 patients treated at the lowest expanded dose of 60 mg/day evaluated at three months, 43 percent showed a >50 percent decline in PSA levels from baseline. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression.

Medivation expects to complete the study, and report final top-line results, in 2008. If these results are positive, Medivation expects to seek U.S. Food and Drug Administration (FDA) agreement to enter pivotal Phase 3 registration study in castration-resistant prostate cancer.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and castration-resistant (also known as hormone-refractory) prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2007, include information about additional factors that could affect the Company's financial and operating results.

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Announces Senior Management Promotions
2. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
3. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
5. Boston Scientific Announces Japanese Approval of Heart Failure Lead
6. Vasogen Announces Implementation of Strategic Restructuring Plan
7. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
8. EXL Announces Appointment of Rembert de Villa as Head of Transformation Services
9. Botaneco Announces Launch of Second Generation Oleosome Product
11. Signalife Announces Webcast
Post Your Comments:
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions ... Melanie Aregger to serve as Chief Operating Officer. , Having joined InSphero ... team and was promoted to Head of InSphero Diagnostics in 2014. There ...
(Date:11/24/2015)... VILLAGE, Nev. , Nov. 24, 2015  PDL BioPharma, ... John P. McLaughlin , the company,s president and chief executive ... Jaffray Healthcare Conference next week in New York ... will occur on Tuesday, December 1, 2015 at 9:30 a.m. ... Presentations." Please connect to the website at least 15 minutes ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):